SCHEMBL6507808

SCHEMBL6507808

COc1ccc(Sc2cc(N[C@@H](CC(C)C)C(=O)O)nc(Nc3cccc(F)c3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.40
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PTGDR Q13258 1/20 0.38
KEAP1 Q14145 1/20 0.37
KCNH3 Q9ULD8 2/20 0.36
GALR2 O43603 1/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FPR2 P25090 1/20 0.35
SCN9A Q15858 1/20 0.35
POLB P06746 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6512168 0.93 CTSK (0.40) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6512174 0.93 CTSK (0.40) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL8299305 0.93 CTSK (0.38) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6512117 0.87 CTSK (0.38) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6512111 0.87 CTSK (0.38) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6528931 0.86 KCNH3 (0.41) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6513761 0.86 ALDH1A1 (0.39) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6513754 0.86 ALDH1A1 (0.39) CTSKALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL6513421 0.85 PLK4 (0.38) CTSKCYP1A2CYP2D6CYP2C19GALR2
SCHEMBL6513831 0.84 CTSK (0.44) CTSKALDH1A1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed